Search results for RNAi
RNAi community
One keyword maps to one global community path.
People
Not Found
Tweets including RNAi
Arrowhead says its RNAi drug crossed the blood-brain barrier in healthy volunteers and sharply lowered tau, a protein tied to Alzheimer’s.
#longevity# #geroscience# #Arrowhead# #RNAi# #Alzheimers#
Show more
A new chapter in RNAi therapeutics begins today. @CityTx_ makes its Nasdaq debut under the ticker $CTY.
Engineering the next generation of RNAi therapeutics. @CityTx_ begins its next chapter as a #NasdaqListed# company. $CTY
.@CityTx_ is advancing the next generation of RNAi therapeutics with a mission to unlock the technology’s potential to help patients across a wide range of diseases.
That mission reaches a new milestone as [CTY] joins the public markets. Welcome to Nasdaq. #NasdaqListed#
Show more
Breaking the mold with #RNA—a# “ #RNAissance# ” of life science.
.
#RNAtherapeutics#
#RNAdrugs#
#Oligonucleotides#
#mRNAtherapeutics#
#mRNA#
#siRNA#
#RNAi#
#Antisenseoligonucleotides#
#Antisenseoligonucleotides#
#ASO#
#NucleicAcids#
.
Show more
City Therapeutics, an early-stage developer of RNAi-based drugs, jumped 28% after raising about $200 million in an upsized US initial public offering
City Therapeutics, an early-stage developer of RNAi-based drugs, raised $200 million in a US initial public offering priced at the mid-point of its marketed range.
City Therapeutics, an early-stage developer of RNAi-based drugs, is seeking to raise as much as $184.7 million in a US initial public offering
CITY THERAPEUTICS PRICES UPSIZED IPO AT $18 A SHARE, RAISING ABOUT $200 MILLION
The RNAi drug developer sold 11.1M shares and is expected to begin trading on Nasdaq on Oct. 16 under $CTY, with Goldman Sachs, Jefferies and Stifel among the bookrunners, per the company
Show more
